N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. (29th January 2018) - Tan, W W; Hillman, D W; Salim, M; Northfelt, D W; Anderson, D M; Stella, P J; Niedringhaus, R; Bernath, A M; Gamini, S S; Palmieri, F; Perez, E A